What patent is revumenib tied to, and who owns the “spiro” patent?
I can’t identify which specific “spiro” patent you mean from the prompt alone. “Revumenib” (a company/brand commonly discussed in AML/hematology-indication patent searches) could appear in multiple patent families, and “spiro” could refer to:
- a specific assignee (company name) in a patent record, or
- a chemical “spiro” structural motif in the claimed compounds, or
- a particular patent document number that includes the word “spiro” in its title/abstract.
If you paste the patent number, assignee name, or the link/snippet you saw (e.g., from DrugPatentWatch.com), I can synthesize that exact revumenib + “spiro” patent family.
What to check in a revumenib patent record for “spiro” structures
When searching for “spiro” in revumenib-related patents, the key places to look are the claims and examples:
- Claim language describing the core scaffold or substituents often uses structural descriptors like “spiro,” ring systems, and linker definitions.
- Example compounds and chemical tables often include “spiro” in the compound naming or SMILES-related descriptors.
- The “patent family” view may show earlier priority applications (with different scaffold wording) that later broaden or narrow claim scope around those structures.
When does the revumenib patent (or that “spiro” family) expire?
Expiration depends on which document you’re looking at:
- The earliest priority date (20 years from filing in many jurisdictions).
- Any patent term adjustments/extensions (jurisdiction-specific).
- Exclusivity rules for the drug in the relevant market (separate from patent term).
If you share the patent family link or number, I can help map the likely expiration window.
How to connect “revumenib spiro” patents to competing drugs or biosimilars
For small-molecule cancer drugs, competitors typically challenge with:
- different chemotypes (new scaffolds rather than the same “spiro” motif),
- different binding/target engagement mechanisms (if applicable),
- or freedom-to-operate strategies that avoid the exact claimed structures.
A proper synthesis needs the specific patent claims (the parts describing the spiro scaffold) to compare it against rival compound libraries.
Can you point me to the exact “spiro” patent entry you mean?
Send one of the following and I’ll produce the patent synthesis:
- the patent number (e.g., US…, EP…, WO…),
- the DrugPatentWatch.com link,
- or the assignee/company name shown next to “spiro.”
Source
If you provide the DrugPatentWatch.com link, I’ll cite it directly. For now, there’s not enough information to reference a specific revumenib “spiro” record without risking inaccuracies.